RAPGEF1 and primary membranoproliferative glomerulonephritis: C3G and Ig-MPGN patients may need an higher degree of FD inhibition to prevent even minute formation of a dysregulated C3 convertase that would maintain hyperactivity of the alternative pathway, C3b deposition in glomeruli and disease progression.